Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, By Route of Administration, By Indication, By Distribution Channel, By Geography

Description

Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at USD 23.72 Bn in 2026 and is expected to reach USD 30.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 23.72 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.50%	2033 Value Projection:	USD 30.18 Bn

Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body's own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others

Market Dynamics

Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug 'Adalimumab' under the brand name 'Mabura' in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021-2033)
Synthetic (sDMARD)
- Conventional synthetic (csDMARDs)
Methotrexate
Sulfasalazine
Leflunomide
Hydroxychloroquine
Gold Salts
Targeted synthetic DMARDs (tsDMARDs)
Biological DMARDs (bDMARD)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
Others
By Route of Administration (Revenue, USD Bn, 2021-2033)
Oral
Parenteral
Others
By Indication (Revenue, USD Bn, 2021-2033)
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Systemic Lupus Erythematosus
Others
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Pfizer
Hoffman-La Roche AG
Johnson & Johnson
AbbVie Inc.
Eli Lilly & Company
Amgen Inc.
Swedish Orphan Biovitrum AB
Bristol-Myers Squibb Company
UCB S.A.
Gilead Sciences, Inc.
Cumberland Pharmaceuticals Inc.

Product Code: CMI5185

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Conventional synthetic (csDMARDs)
  - Methotrexate
  - Sulfasalazine
  - Leflunomide
  - Hydroxychloroquine
  - Gold Salts
Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Original DMARDs (boDMARDs)
  - Biosimilar DMARDs (bsDMARDs)
  - Primary
  - Secondary
  - Tertiary
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Administration, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffman-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli Lilly & Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Swedish Orphan Biovitrum AB
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- UCB S.A.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Gilead Sciences, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cumberland Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views

10. Section

References
Research Methodology
About Us